Skip to content
cardio.webdr
ToolsSpecialtiesEchoHeart sounds
ToolsSpecialtiesEchoHeart soundsFavoritesPrivate notes
cardio.webdr

Clinical clarity, in seconds. Built for focused decisions—not data collection.

Patient inputs stay on this device.
ExploreAll toolsSpecialtiesEchocardiographyHeart sounds
Your workspaceFavoritesPrivate notesCalculation historyOffline access
PlatformAboutFAQDevelopersFeedbackContact
© 2026 CardioWebdr Clinical support, not a substitute for judgment.PrivacyTermsStorageSupportReport an issue
All tools/Cardio-Oncology Scores
Interactive worksheet8 clinical inputsPatient data not stored

HFA-ICOS Dynamic Surveillance Index Calculator

HFA-ICOS Dynamic Surveillance Index: Explanation and Clinical Context The HFA-ICOS Dynamic Surveillance Index is a risk stratification tool developed by the Heart Failure Association of the European Society of Cardiology and the International Cardio-Oncology Society. It is designed to assess the cardiovascular risk in oncology patients prior to initiating potentially cardiotoxic anti-cancer therapies. The index consi

Interactive worksheet

Clinical inputs

0/8 filled
Hypertension
Diabetes Mellitus
Hyperlipidemia
Smoking
Family History of Cardiovascular Disease
Inputs stay on this device
Active structured worksheetActive local worksheet: mapped inputs can be completed, validated, copied, saved, and exported on this device. No numerical score is asserted unless its formula is independently reproducible.
Clinical contextWhy this tool matters and how to interpret it

Understand the result,
not just the number.

HFA-ICOS Dynamic Surveillance Index: Explanation and Clinical Context The HFA-ICOS Dynamic Surveillance Index is a risk stratification tool developed by the Heart Failure Association of the European Society of Cardiology and the International Cardio-Oncology Society. It is designed to assess the cardiovascular risk in oncology patients prior to initiating potentially cardiotoxic anti-cancer therapies. The index considers various patient-related factors, including age, sex, and the presence of cardiovascular risk factors such as hypertension, diabetes, hyperlipidemia, smoking, and family history of cardiovascular disease.

Based on these factors, patients are categorized into low, moderate, high, or very high-risk groups, which guides clinicians in tailoring surveillance and management strategies to mitigate the risk of cardiovascular toxicity during cancer treatment. The tool has been validated in multiple studies and is recommended for use in clinical practice to enhance patient safety and optimize therapeutic outcomes.

Evidence & references1 primary source mapped
  1. Source 1

    Rivero-Santana, B., et al. (2025). Anthracycline-induced cardiovascular toxicity: validation of the HFA-ICOS risk assessment tool in a real-world cohort. European Heart Journal, 46(3), 273-280. doi:10.1093/eurheartj/ehaa999

Clinical discussionModerated, tool-specific conversation

Loading discussion…

Moderated before publishingNever include patient identifiers.

Workspace mode

Structured worksheet

Active local worksheet: mapped inputs can be completed, validated, copied, saved, and exported on this device. No numerical score is asserted unless its formula is independently reproducible.

On this pageWorksheet Clinical context References Discussion

Privacy by default

Inputs, results, favorites, and notes remain in your browser unless you explicitly export them.

Privacy details
Report formula or content issue
Continue exploring

Related clinical tools

More in this specialty
Interactive worksheet

CHOP/Anthracycline Cumulative Dose Score Calculator

Cardio-Oncology Scores
Interactive worksheet

LV GLS Drop >15% Calculator

Cardio-Oncology Scores
Interactive worksheet

Global Longitudinal Strain Early Change Index (GLS-ECI) Calculator

Cardio-Oncology Scores
Interactive worksheet

Mayo Clinic Cardiotoxicity Risk Score Calculator

Cardio-Oncology Scores
Clinical structure and calculation context point directly to Source 1; additional primary references remain listed for auditability.